Beneficiary Advisory Panel Handout Uniform Formulary Decisions 24 June 2010
|
|
|
- Lester May
- 5 years ago
- Views:
Transcription
1 Beneficiary Advisory Panel Handout Uniform Formulary Decisions 24 June 2010 PURPOSE: The purpose of this handout is to provide BAP Committee members with a reference document for the relative clinical effectiveness presentations for each Uniform Formulary (UF) Class review 24 Jun 2010 Beneficiary Advisory Panel Meeting Page 1 of 10
2 Table 1: Uniform Formulary Recommendations from the May 2010 DoD P&T Committee Meeting Antilipidemic -1s Drug Class Generic Name (Brand) Formulations Antilipidemic 1s - Statins, Statin Combinations, Ezetimibe, & Niacin Uniform Formulary Statins Generics Available? Atorvastatin (Lipitor) tabs No Fluvastatin (Lescol) tabs No Fluvastatin ER (Lescol XL) tabs No Lovastatin IR (Mevacor) tabs Lovastatin ER (Altoprev) tabs No Pravastatin (Pravachol) tabs Simvastatin (Zocor) tabs Rosuvastatin (Crestor) tabs No Statin Combinations Atorvastatin / amlodipine (Caduet) tabs No Lovastatin / niacin ER (Advicor) tabs No Simvastatin / niacin ER (Simcor) Tabs No Simvastatin/ ezetimibe (Vytorin) tabs No Add-on therapies Ezetimibe (Zetia) tabs No Niacin ER (Niaspan) tabs No Niacin IR (Niacor) tabs Nothing non-formulary (NF) but step therapy applies. Generics, atorvastatin (Lipitor) step preferred Recommended implementation period 60 days Figure 1: High Intensity Statins 24 Jun 2010 Beneficiary Advisory Panel Meeting Page 2 of 10
3 Figure 2: Low to Moderate Intensity Statins Figure 3: Lipid Add-On Therapy 24 Jun 2010 Beneficiary Advisory Panel Meeting Page 3 of 10
4 Table 2: Expected Mean LDL Reductions, by Statin and Dose Statin Expected Mean LDL Reduction Mevacor, Altoprev (lovastatin) Pravachol (pravastatin) Zocor (simvastatin) Lescol, Lescol XL (fluvastatin) Lipitor (atorvastatin) Crestor (rosuvastatin) 25 to 30% 20 mg 20 mg 10 mg 40 mg 30 to 40% mg 40 mg 20 mg 80 mg (XL only) 10 mg 40 to 45% IR: 80 mg (40 mg x 2) ER: 60 mg 80 mg 40 mg or Vytorin 10/10 mg 20 mg 5 mg 45 to 50% 80 mg or Vytorin 10/20 mg 40 mg 10 mg Please note: ezetimibe (Zetia) or 50 to 55% niacin generally decrease LDL up to an additional 15% Vytorin 10/40 mg 80 mg 20 mg >55% Vytorin 10/80 mg 40 mg IR = immediate release; ER = extended release Vytorin = simvastatin/ezetimibe 24 Jun 2010 Beneficiary Advisory Panel Meeting Page 4 of 10
5 Table 3: Uniform Formulary Recommendations from the May 2010 DoD P&T Committee meeting Alpha Blockers for BPH Alpha-1 blocker BPH Agents UF Status / Implementation Period Generic Name (Brand) Formulations Generics Available? Flomax (tamsulosin) cap Uroxatral (alfuzosin) extended release cap No Hytrin (terazosin) tab/cap Cardura (doxazosin) tab Non-formulary Cardura (doxazosin) - recommended for NF May 2010 Rapaflo (silodosin) recommended to remain NF May 2010 tab cap No Recommended implementation period 60 days Figure 4: Alpha Blockers 24 Jun 2010 Beneficiary Advisory Panel Meeting Page 5 of 10
6 Table 4: Fentanyl Transmucosal Soluble Film (Onsolis): Uniform Formulary Recommendations from May 2010 for the Narcotic Analgesics Narcotic Analgesics UF Status / Implementation Period Generics Generic Name (Brand) Formulations Available? High-potency single analgesic agents Long-acting agents (> 12 hour duration) Fentanyl transdermal system (Duragesic) patch Morphine sulfate ER 24 hr (Kadian, Avinza) cap No Morphine sulfate ER 12 hr (MS Contin, Oramorph) tab, soln, supp, inj Morphine sulfate ER/Naltrexone (Embeda) caps No Oxycodone ER (Oxycontin) tabs No Oxymorphone (Opana ER) tabs No Short acting agents (<12 hour duration) Codeine tabs, soln, inj Fentanyl citrate buccal (Fentora) tabs No Fentanyl citrate transmucosal (Actiq) lozenges Uniform Formulary Fentanyl citrate transmucosal soluble film (Onsolis) Recommended for UF May 2010 Soluble Film No, except for Hydromorphone (Dilaudid) tab, inj, liquid 1 mg tab Levorphanol (Levo-Dromoran) tab, inj Meperidine (Demerol) tab, soln, inj Meperidine / promethazine (Mepergan Fortis) caps Methadone (Dolophine) tab, oral conc, soln, inj Morphine sulfate IR tabs Opium tincture Opium / belladonna alkaloids supp Oxycodone IR caps, oral conc, soln Oxymorphone IR (Opana) tabs No High-potency combination agents Oxycodone /APAP (e.g., Percocet, Tylox, others) tab, cap, soln Oxycodone / ASA (Percodan) tabs Low potency single analgesic agents Buprenorphine (Buprenex) inj (excludes SL tabs) Butorphanol (Stadol) nasal spray, inj Pentazocine / naloxone (Talwin NX) tabs Propoxyphene (Darvon) caps, tabs Nalbuphine (Nubain ) not a controlled substance) Tramadol IR(Ultram) not a controlled substance tab Inj 24 Jun 2010 Beneficiary Advisory Panel Meeting Page 6 of 10
7 Table 4: Fentanyl Transmucosal Soluble Film (Onsolis): Uniform Formulary Recommendations from May 2010 for the Narcotic Analgesics (continued) Uniform Formulary Non-Formulary Low potency combination agents Codeine / APAP (Tylenol with codeine) tabs, elixir, oral susp Codeine / ASA tabs Codeine / ASA / carisoprodol (Soma) tabs Codeine / caffeine / butalbital / APAP (Fioricet with codeine) Codeine / caffeine / butalbital / ASA (Fiorinal with caffeine) Dihydrocodeine / caffeine / APAP e.g., Panlor DC, Panlor SS) caps caps, tabs caps, tabs Dihydrocodeine / caffeine / ASA (Synalgos-DC) caps Hydrocodone / APAP (e.g., Lortab, Lorcet, Vicodin, others) caps Pentazocine / APAP (Talacen) tabs Propoxyphene / APAP (Darvocet) tabs Propoxyphene / ASA / caffeine (Darvon Compound 65) Tramadol/APAP (Ultracet) not a controlled substance Low potency single analgesic agents caps Tramadol extended release (Ultram ER) tab No Tramadol extended release (Ryzolt) tab No High potentcy single analgesic agents; short-acting agents (<12 hours duration) tab Tapentadol (Nucynta) tab No Recommended Implementation Period Not Applicable for Onsolis Figure 5: Narcotic Analgesics - Onsolis 24 Jun 2010 Beneficiary Advisory Panel Meeting Page 7 of 10
8 Table 5: Sumatriptan needle-free injection (Sumavel DosePro): Uniform Formulary Recommendations from May 2010 for the Triptans UF Status / Implementation Period Formulary Non-Formulary Recommended implementation period Generic Name (Brand) 5-Hydroxytrptamine Agonists (Triptans) Formulations Generics Available? Eletriptan (Relpax) Tabs No Sumatriptan (Imitrex) Tabs, injection, nasal spray Sumatriptan / naproxen (Treximet) Tabs No Rizatriptan (Maxalt) Tabs, orally dissolving tabs (ODT) Zolmitriptan (Zomig) Tabs, ODT, nasal spray No Almotriptan (Axert) Tabs No Frovatriptan (Frova) Tabs No Naratriptan (Amerge) Tabs No Sumatriptan (Sumavel DosePro) Recommended for NF May days Needle-free injection No No Figure 6 Triptans Sumavel DosePro Triptan Utilization All POS Apr 07 Mar TOTAL # Prescriptions ALMOTRIPTAN MALATE FROVATRIPTAN SUCCINATE RIZATRIPTAN BENZOATE SUMATRIPTAN SUCC/NAPROXEN SOD ELETRIPTAN HYDROBROMIDE NARATRIPTAN HCL SUMATRIPTAN ZOLMITRIPTAN SOURCE: PDTS 24 Jun 2010 Beneficiary Advisory Panel Meeting Page 8 of 10
9 Table 6: Formulary Implementation Plan Summary February 2010 Meeting Drug Class May 10 Antilipidemic-1s None May 10 Alpha Blockers for BPH Non-Formulary Medications Doxazosin ER (Cardura XL) Silodosin (Rapaflo) Total Beneficiaries Affected (# of patients affected) 60,310 (new users will hit step) Beneficiaries Affected by POS MTF Retail Mail Order Implementation Plan First Wednesday X days after the decision date 19,125 31,227 9, days 1, days Step Therapy ; requires trial of a generic statin or Lipitor ; requires trial of generic tamsulosin or Uroxatral May 10 Narcotic Analgesics None (Note: Fentanyl transmucosal soluble film; Onsolis recommended for UF) N/A No May 10 Triptans Sumatriptan needle-free injection (Sumavel DosePro) days No Basal Insulins Insulin detemir pens (Levemir FlexPen) 11,782 3,510 6,226 2, days No Antihemophilic Factors Factor VIII: Advate, Helixate, Hemofil M, Monoclate, Recombinate Factor IX: Mononine; Factor VIII/vWF: Humate-P Human PCC: Bebulin VH Inhibitor bypassing product: Feiba VH days No Narcotic Analgesics Not applicable (Note: Embeda remains Uniform Formulary) N/A No 24 Jun 2010 Beneficiary Advisory Panel Meeting Page 9 of 10
10 Meeting Drug Class Non-Formulary Medications Total Beneficiaries Affected (# of patients affected) Beneficiaries Affected by POS MTF Retail Mail Order Implementation Plan First Wednesday X days after the decision date Step Therapy ADHD drugs Not applicable (Note: Intuniv remains Uniform Formulary) N/A No RAAs Telmisartan/amlodipine (Twynsta) days No RAAs Aliskiren/valsartan (Valturna) days No Newer Sedative Hypnotics Zolpidem sublingual tablets (Edluar) days ; zolpidem IR tablets (Ambien generic) in front of step 24 Jun 2010 Beneficiary Advisory Panel Meeting Page 10 of 10
Beneficiary Advisory Panel Handout Uniform Formulary Decisions 25 March 2010
Beneficiary Advisory Panel Handout Uniform Formulary Decisions 25 March 2010 PURPOSE: The purpose of this handout is to provide BAP Committee members with a reference document for the relative clinical
Beneficiary Advisory Panel Handout Uniform Formulary Decisions 6 Jan 2011
Beneficiary Advisory Panel Handout Uniform Formulary Decisions 6 Jan 2011 PURPOSE: The purpose of this handout is to provide BAP Committee members with a reference document for the relative clinical effectiveness
Texas Prior Authorization Program Clinical Edit Criteria
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Drugs requiring prior authorization: the list of drugs requiring prior authorization
Xyrem (Sodium Oxybate)
Texas Prior Authorization Program Clinical Criteria Drug/Drug Class Clinical Criteria Information Included in this Document Drugs requiring prior authorization: the list of drugs requiring prior authorization
Cigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Controlled Substance Analgesic and Narcotic Antagonist Quantity Limitations Table of Contents Coverage Policy... 1 General Background... 6 Coding/Billing
Opiate/Benzodiazepine/Muscle Relaxant Combinations
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Opiate/Benzodiazepine/Muscle Relaxant Combinations Clinical Edit Information Included in this Document Drugs requiring prior authorization:
Capital BlueCross Open/Closed Formulary Update (1 st Quarter 2017)
Capital BlueCross Open/Closed Formulary Update (1 st Quarter 2017) The Capital BlueCross formulary is a reference list of prescription drugs that contains a wide range of generic and brand drugs that have
DOD PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE UNIFORM FORMULARY BENEFICIARY ADVISORY PANEL
DOD PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE UNIFORM FORMULARY BENEFICIARY ADVISORY PANEL I. UNIFORM FORMULARY REVIEW PROCESS Under 10 U.S.C. 1074g, as implemented by 32
New Hampshire Healthy Families CLINICAL POLICY
New Hampshire Healthy Families CLINICAL POLICY DEPARTMENT: Pharmacy DOCUMENT NAME: Opioid Analgesics PAGE: 1 o f 6 REFERENCE NUMBER: NH.PPA.13 EFFECTIVE DATE: 6/1/2016 REPLACES DOCUMENT: N/A RETIRED: REVIEWED:
APPROVED PA CRITERIA. Initial Approval: January 10, 2018 Revised Dates: April 11, 2018 CRITERIA FOR PRIOR AUTHORIZATION
Initial Approval: January 10, 2018 Revised Dates: April 11, 2018 CRITERIA FOR PRIOR AUTHORIZATION PROVIDER GROUP Pharmacy Opioid Products Indicated for Pain Management MANUAL GUIDELINES All dosage forms
Opioid Analgesic/Opioid Combination Products
Market DC Opioid Analgesic/Opioid Combination Products Override(s) Quantity Limit Approval Duration 1 year Generic Name Brand Name Quantity Limit APAP/Caf/Dihydrocodeine 320.5mg/30mg/16mg APAP/Caf/Dihydrocodeine
PRESCRIPTION DRUG PROGRAM FORMULARY UPDATES Select Formulary October 1, 2018 Updates. Formulary. Alternatives
PRESCRIPTION DRUG PROGRAM FORMULARY UPDATES Select October 1, 2018 Updates Drug Name efavirenz 600mg (Brand = Sustiva ) trientine (Brand = Syprine ) hydrocortisone lot 0.1% (Brand = Locoid ) sumatriptan-naproxen
DEPARTMENT OF DEFENSE PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS. February 201 0
DEPARTMENT OF DEFENSE PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS I. CONVENING February 201 0 The Department of Defense (DoD) Pharmacy and Therapeutics (P&T) Committee convened at 0800 hours on
Opioid Management Program May 2018
Opioid Management Program May 2018 What Is the Opioid Management Program? This program is based on guidelines developed by the U.S. Centers for Disease Control and Prevention (CDC). It consists of daily
Opioid Management Program October 2018
Opioid Management Program October 2018 What Is the Opioid Management Program? This program is based on guidelines developed by the U.S. Centers for Disease Control and Prevention (CDC). It consists of
Uniform Formulary Decisions 9 January 2014
Beneficiary Advisory Panel Handout Uniform Formulary Decisions 9 January 2014 Purpose: The purpose of this handout is to provide the BAP members with a reference document for the clinical effective presentation
CNS DEPRESSANT OVERDOSE
Signs and symptoms of CNS depressant overdose include: altered mental status, respiratory depression, hypotension, bradycardia, pulmonary edema, coma, and constricted pupils (opioids only). The following
Responsible Quantity Program Effective 4/1/10. Abilify oral solution
Abilify Abilify Discmelt Abilify oral solution Aciphex Actiq Page 1 of 9 750 ml 120 units Actonel 5 mg, 30 mg Actonel 35 mg 4 tabs Actonel 75 mg 2 tabs Actonel 150 mg 1 tab Actonel with Calcium Adcirca
UF Decision Report FY06-07 Beneficiary Advisory Panel 10 Jan 2008
UF Decision Report FY06-07 Beneficiary Advisory Panel 10 Jan 2008 Promoting high quality, cost effective drug therapy throughout the Military Health System UF Decisions, May 07 Class FY05 rank, total $
Opioid Analgesic/Opioid Combination Products
Opioid Analgesic/Opioid Combination Products Override(s) Quantity Limit Approval Duration 1 year Generic Name Brand Name Quantity Limit 320.5mg/30mg/16mg 356.4mg/30mg/16mg 325mg/30mg/16mg Trezix (new formulation)
Pharmacy Medical Necessity Guidelines: Opioid Analgesics
Pharmacy Medical Necessity Guidelines: Effective: January 1, 2019 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy (RX) or Medical (MED) Benefit
Pequot Health Care Opioid Analgesic Quantity Program*
Pequot Health Care 1 Annie George Drive Mashantucket, CT 06338 Phone: 1-888-779-6638 Fax: 1-860-396-6494 Pequot Health Care Opioid Analgesic Quantity Program* Effective January 2018 *Quantity Program limits
Generic Label Name Drug Strength Dosage Form Example Product (s) MME/Unit ACETAMINOPHEN WITH CODEINE
STATE OF TENNESSEE DEPARTMENT OF FINANCE AND ADMINISTRATION DIVISION OF HEALTH CARE FINANCE AND ADMINISTRATION BUREAU OF TENNCARE 3 Great Circle Road NASHVILLE, TENNESSEE 37243 This notice is to advise
MEDICARE Program Policies & Procedures POLICY NUMBER: Medicare D-111
POLICY: Medicare Part D Formulary-Level Cumulative Opioid and Opioid/Buprenorphine POS Edits MEDICARE Program Policies & Procedures POLICY NUMBER: Medicare D-111 Policy for contracts H3351, S3521 and H3335
Medical Policy An independent licensee of the Blue Cross Blue Shield Association
Opioid Immediate Release Page 1 of 13 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Opioid Immediate Release Prime Therapeutics will review Prior Authorization
Section 2 Class III, IV & V Pharmaceuticals Page 13
Section 2 Class III, IV & V Pharmaceuticals Page 13 ACETAMINOPHEN W/ CODEINE #3 30MG TABS (GENERIC TYLENOL) #100 41.99 ACETAMINOPHEN W/ CODEINE #3 30MG TABS #1000 298.99 ACETAMINOPHEN W/ CODEINE #4 60MG
Prior Authorization for Opioid Products Indicated for Pain Management
Kansas Medical Assistance Program PA Phone 800-933-6593 PA Fax 800-913-2229 Amerigroup PA Pharmacy Phone 855-201-7170 PA Pharmacy Fax 800-601-4829 Sunflower PA Pharmacy Phone 877-397-9526 PA Pharmacy Fax
10 mg hydrocodone equals how much oxycodone
Cari untuk: Cari Cari 10 mg hydrocodone equals how much oxycodone Posts about dilaudid 8 vs oxycodone 30 written by buyprescriptionmedication. Can you help me with the conversion of Oxycodone IR (5mg tab)
CHAMP: Bedside Teaching TREATING PAIN. Stacie Levine MD. What is the approach to treating pain in the aging adult patient?
CHAMP: Bedside Teaching TREATING PAIN Stacie Levine MD Teaching Trigger: An older adult patient is identified as having pain. Clinical Question: What is the approach to treating pain in the aging adult
Beneficiary Advisory Panel Handout Uniform Formulary Decisions 14 Jan 2010
Beneficiary Advisory Panel Handout Uniform Formulary Decisions 14 Jan 21 PURPOSE: The purpose of this handout is to provide BAP Committee members with a reference document for the relative clinical effectiveness
Disposal by Flushing of Certain Unused Medicines: What
Disposal by Flushing of Certain Unused Medicines: What You Should Know Drugs Page 1 of 5 Disposal by Flushing of Certain Unused Medicines: What You Should Know Overview Frequently Asked Questions List
1/29/2013. Schedule II Controlled Substances: Basics and Beyond. Controlled Substances. Controlled Substances, Schedule I
chedule II Controlled ubstances: Basics and Beyond James L. Besier, Ph.D., R.Ph., FAHP Adjunct Associate Professor College of Nursing Adjunct Assistant Professor James L. Winkle College of Pharmacy University
: Opioid Quantity Limits
March 7, 2017 2017-09: Opioid Quantity Limits The Louisiana Department of Health (LDH), in conjunction with the Louisiana Medicaid Drug Utilization Review (DUR) Board, has revised quantity limits for selected
Bree Collaborative AMDG Opioid Prescribing Guidelines Workgroup. Opioid Prescribing Metrics - DRAFT
Bree Collaborative AMDG Opioid Prescribing Guidelines Workgroup Opioid Prescribing Metrics - DRAFT Definitions: Days Supply: The total of all opioid prescriptions dispensed during the calendar quarter
Slide 1. Slide 2. Slide 3. Opioid (Narcotic) Analgesics and Antagonists. Lesson 6.1. Lesson 6.1. Opioid (Narcotic) Analgesics and Antagonists
Slide 1 Opioid (Narcotic) Analgesics and Antagonists Chapter 6 1 Slide 2 Lesson 6.1 Opioid (Narcotic) Analgesics and Antagonists 1. Explain the classification, mechanism of action, and pharmacokinetics
Morphine IR Hydromorphone IR Oxymorphone IR. Morphine IR, Dilaudid IR (hydromorphone), Opana IR (oxymorphone),
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.33 Subject: Morphine IR Drug Class Page: 1 of 11 Last Review Date: December 8, 2017 Morphine IR Hydromorphone
TRICARE Uniform Formulary. Pre-Authorization Requirements
TRICARE Uniform Formulary Pre-Authorization Requirements The Department of Defense (DoD) requires pre-authorization on select medications. These medications are on the DoD s pre-authorization list because
Conversion chart from fentanyl to opana er
Conversion chart from fentanyl to opana er (e.g., Nucynta). Both opioid products involved in conversion are one of the following: morphine, oxycodone, oxymorphone, hydromorphone (not extended- release),
AETNA BETTER HEALTH Prior Authorization guideline for Narcotic Analgesic Utilization
AETNA BETTER HEALTH Prior Authorization guideline for Narcotic Analgesic Utilization Policy applies to all formulary and non-formulary schedules II V opioid narcotics, including tramadol and codeine, as
Abortive Agents. Available Strengths. Formulary Limits. Tablet: 5mg, 10mg ODT: 5mg, 10 mg 25mg, 50mg, 100mg. 5mg/act, 20mg/act
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Migraine Therapy P&T DATE: 9/12/2017 CLASS: Neurological Disorders REVIEW HISTORY 12/16, 9/15, 2/15, 2/10, 5/07 LOB: MCL
PAIN. TREATMENT TABLES Analgesics. NON-OPIOID ANALGESICS Generic Name Trade Names (Examples) Duration Initial Dose
NON-OPIOID SHORT-ACTING LONG-ACTING **** O PAIN TREATMENT TABLES Analgesics NON-OPIOID ANALGESICS Generic Name Trade Names (Examples) Duration Initial Dose Tramadol 50 mg Ultram Every 4 hours 1-2 tabs,
Michigan Department of Community Health Quantity Limitations
Abstral (fentanyl) sl tab all strength Acetaminophen Actonel Actonel 35mg Adderall XR 5mg, 10mg, 15mg 240 per 34 days 3 gm/day 2 every 28 days 4 every 28 days Advair Diskus. No more than 180 every 30 days
DEPARTMENT OF DEFENSE PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INTERIM MEETING
DEPARTMENT OF DEFENSE PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INTERIM MEETING Addendum December 17, 2013 I. UNIFORM FORMULARY (UF) DRUG CLASS REVIEWS A. Anti-Lipidemic-ls (LIP-ls) Background-New
Pharmacy Updates Summary
All of the following changes were reviewed and approved by the SFHP Pharmacy & Therapeutics (P&T) Committee on 4/16/2014 Effective date: 5/15/2014 Therapeutic Classes reviewed: ADHD Ophthalmic antihistamines
Opioid Capture in the AHSQC Can we reduce use by measuring it? Michael Reinhorn MD, MBA, FACS Dept of Surgery, Newton Wellesley Hospital
Opioid Capture in the AHSQC Can we reduce use by measuring it? Michael Reinhorn MD, MBA, FACS Dept of Surgery, Newton Wellesley Hospital Disclosure Davol/Bard Consultant Medtronic Physician Advisory Honorarium
Disposal of Unused Medicines: What You Should Know
1 of 8 3/12/16 11:14 PM U.S. Food and Drug Administration Protecting and Promoting Your Health Disposal of Unused Medicines: What You Should Know Topics on this page Overview List of Medicines Recommended
MTF Quarterly Webcast
TMA Fort Sam Houston, TX MTF Quarterly Webcast LTC Stacia Spridgen Director, 1 Introduction Greetings from the PEC Purpose of the Quarterly MTF Webcast DCO Ground Rules Type questions into DCO system Put
Cigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Opioid Therapy Table of Contents Coverage Policy... 1 General Background... 4 Coding/Billing Information... 7 References... 7 Effective Date..1/1/2018 Next
Disposal of Unused Medicines: What You Should Know
1 of 8 04/27/2016 1:37 AM U.S. Food and Drug Administration Protecting and Promoting Your Health Disposal of Unused Medicines: What You Should Know Topics on this page (http://www.fda.gov/aboutfda/aboutthiswebsite
Equianalgesic Dosing of Opioids for Pain Management
PL Detail-Document #300405 This PL Detail-Document accompanies the related article published in PHARMACIST S LETTER / PRESCRIBER S LETTER April 2014 Equianalgesic Dosing of Opioids for Pain Management
A Statewide Evaluation of Opioid Prescribing Patterns with an Emphasis on Drug Diversion and Substance Abuse
A Statewide Evaluation of Opioid Prescribing Patterns with an Emphasis on Drug Diversion and Substance Abuse INVESTIGATIVE TEAM: STEERING COMMITTEE FOR THE TUFTS HEALTH CARE INSTITUTE ON OPIOID RISK MANAGEMENT
Prescription Drug Monitoring Reference Guide: 2017
Prescription Drug Monitoring Reference Guide: 2017 Prescription Drug Monitoring Test Codes Test Codes Drug/Drug Class P P,D,M P,D D,M D Alcohol Metabolites 90079 16910 92142 16217 Amphetamines 92222 70245
Proposed Changes to Existing Measure for HEDIS : Use of Opioids at High Dosage (UOD)
Proposed Changes to Existing Measure for HEDIS 1 2020: Use of Opioids at High Dosage (UOD) NCQA seeks comments on proposed revisions to the Use of Opioids at High Dosage HEDIS measure. The current measure
Controlled Substance Prescribing Handbook. University of South Alabama College of Medicine Department of Family Medicine
Controlled Substance Prescribing Handbook University of South Alabama College of Medicine Department of Family Medicine Controlled Substance Prescribing Handbook University of South Alabama College of
Hydrocodone 10mg vs oxycodone 10 mg. What is the difference between oxycontin and oxycodone hcl 1 acetaminophen with oxycodone and roxicodone 5mg
TE Te Hydrocodone 10mg vs oxycodone 10 mg What is the difference between oxycontin and oxycodone hcl 1 acetaminophen with oxycodone and roxicodone 5mg Manufacturer of oxycodone hcl 15 mg tablet side effects
Appendix A. Socio-demographic Characteristics of Survey Respondents Compared to Current Population Survey (2013) Data
Data Supplement for Kennedy-Hendricks et al. (10.1176/appi.ps.201600056) Appendix A. Socio-demographic Characteristics of Survey Respondents Compared to Current Population Survey (2013) Data Un-weighted
Committee Approval Date: September 12, 2014 Next Review Date: September 2015
Medication Policy Manual Topic: fentanyl-containing medications: - Actiq, fentanyl citrate oral transmucosal lozenges - Abstral fentanyl sublingual tablets - Fentora, fentanyl buccal tablet - fentanyl
Opioids: Use, Abuse and Cause of Death. Jennifer Harmon Assistant Director - Forensic Chemistry Orange County Crime Laboratory
Opioids: Use, Abuse and Cause of Death Jennifer Harmon Assistant Director - Forensic Chemistry Orange County Crime Laboratory jharmon@occl.ocgov.com Opioid: Any psychoactive chemical that resembles morphine
Physiological and psychological experience for patients Can be seen as body s defense mechanism physiologically
Pain Physiological and psychological experience for patients Can be seen as body s defense mechanism physiologically Avoid damaging situation Seek help Psychological factors can increase or decrease perception
Connecticut Medicaid P&T Meeting Minutes June 5, 2008
Connecticut Medicaid P&T Meeting Minutes June 5, 2008 The meeting started at 6:30 pm Attendance Present Members: Carl Sherter, MD Kenneth Marcus, MD Lester Silberman, MD Peggy Manning Memoli, Pharm D Richard
Triptan Quantity Limit
*- Florida Healthy Kids Triptan Quantity Limit Override(s) Quantity Limit Approval Duration 1 year Oral Tablets Axert (almotriptan) tablets Relpax (eletriptan) tablets 6 tablets (6.25 mg) 12 tablets (12.5
Doctor discussion guide:
Doctor discussion guide: MAnaging Cholesterol Bring this printout to your next doctor s appointment. It will help you and your doctor work together to set goals for treatment, evaluate the success of your
USE OF OPIODS AT HIGHER DOSES IN PERSONS WITHOUT CANCER: MORPHINE EQUIVALENT DOSE EDIT
BACKGROUND: USE OF OPIODS AT HIGHER DOSES IN PERSONS WITHOUT CANCER: MORPHINE EQUIVALENT DOSE EDIT Approximately 10% of patients who are prescribed opioids and seek care from multiple doctors, are prescribed
Carefirst. +.V Family of health care plans
Family of health care plans Prior Authorization Form 1361M Opioids ER MME Limit and Post Limit This fax machine is located in a secure location as required by HPAA regulations. Complete/review information,
Extended Release Opioid Drugs
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Section: Prescription Drugs Effective Date: January 1, 2019 Subject: Extended Release Opioid Drugs Page:
High ( 50%) Restrictions mg 20-40mg PA; TS ⱡ 15 ⱡ
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Cholesterol P&T DATE: 5/9/2017 THERAPEUTIC CLASS: Cardiovascular REVIEW HISTORY: 5/16, 5/15, 2/14, 5/12, LOB AFFECTED: Medi-Cal
Morphine Sulfate Hydromorphone Oxymorphone
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.33 Subject: Morphine Drug Class Page: 1 of 12 Last Review Date: September 15, 2017 Morphine Sulfate
Drug Use Evaluation: Short Acting Opioids (SAO)
Drug Use Evaluation: Short Acting Opioids (SAO) Summary Short acting opioid analgesics are one of the most prescribed (top 10) and highest cost (top 20) medication classes for the Oregon Fee For Service
Doctor discussion guide:
Bring this printout to your next doctor s appointment. It will help you and your doctor work together to set goals for treatment, evaluate the success of your treatment, and reduce your risk of side effects.
Pharmacology of Selected Opioid Analgesics
Pharmacology of Selected Opioid Analgesics Harvey Berman, PhD, MPH Department of Pharmacology and Toxicology hberman@buffalo.edu 829-2658 Note: I plan to discuss only some of the slides, the others (O)
Extended Release Opioid Drugs
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.61 Subject: Extended Release Opioid Drugs Page: 1 of 14 Last Review Date: March 16, 2018 Extended
II. UF CLASS REVIEWS SHORT-ACTING BETA AGONISTS (SABAs)
DEPARTMENT OF DEFENSE PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE UNIFORM FORMULARY BENEFICIARY ADVISORY PANEL I. UNIFORM FORMULARY REVIEW PROCESS Under 10 United States Code
Medication Policy Manual. Topic: Immediate-release (IR) Opioid Medication Products for Pain. Date of Origin: January 1, 2018
Independent licensees of the Blue Cross and Blue Shield Association Medication Policy Manual Topic: Immediate-release (IR) Opioid Medication Products for Pain Policy No: dru516 Date of Origin: January
Beneficiary Advisory Panel Handout Uniform Formulary Decisions 23 June 2011
Beneficiary Advisory Panel Handout Uniform Formulary Decisions 23 June 211 PURPOSE: The purpose of this handout is to provide BAP Committee members with a reference document for the relative clinical effectiveness
Pharmacy Medical Necessity Guidelines: Migraine Medications
Pharmacy Medical Necessity Guidelines: Effective: September 18, 2017 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy (RX) or Medical (MED)
Prior Authorization Opioid Overutilization 2017
Drugs Requiring Prior Authorization Label Name ACETAMINOPHEN/CAFFEINE/DIHYDROCODEINE CAPSULE ACETAMINOPHEN/CODEINE SOLUTION ACETAMINOPHEN/CODEINE TABLET ASCOMP/CODEINE CAPSULE BUTALBITAL/CAFFEINE/ACETAMINOPHEN/CODEINE
Levorphanol. Levorphanol Tartrate. Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.59 Subject: Levorphanol Page: 1 of 8 Last Review Date: March 16, 2018 Levorphanol Description Levorphanol
Michigan Department of Health & Human Services Quantity Limitations
Abstral (fentanyl) sl tab all strength Acetaminophen Actonel Actonel 35mg Adderall XR 5mg, 10mg, 15mg Advair Diskus Advair HFA Aero Chambers and Spacers Aerobid Aerobid M Albuterol HFA 90mcg Akynzeo Aldara
used for dealing with anxiety. Both of the drugs are also given to patients for dealing with pain activated by damaged or hypersensitive nerves that i
Aspirin (also classified under NSAIDs or acetylsalicylic acid). Morphine and morphine sustained release (MS-Contin, Avinza, Kadian) Oxymorphone (Opana, Opana ER) Hydrocodone with acetaminophen (Lortab
Pharmacotherapy for opioid addiction. Judith Martin, MD Medical Director BAART Turk Street Clinic San Francisco
Pharmacotherapy for opioid addiction Judith Martin, MD Medical Director BAART Turk Street Clinic San Francisco Disclosure slide No commercial conflicts to disclose. Gaps in current treatment of opioid
Narcotic Equivalence Converter Narcotic Route Dose Duration; Select a drug: mg Convert to: mg Adapted from Tarascon Pocket Pharmacopoeia.
Narcotic Equivalence Converter Narcotic Route Dose Duration; Select a drug: mg Convert to: mg Adapted from Tarascon Pocket Pharmacopoeia. Created: Monday, March 12. Online calculator to convert equianalgesic
Allergic to hydrocodone can i take tramadol
Allergic to hydrocodone can i take tramadol The Borg System is 100 % Allergic to hydrocodone can i take tramadol Dec 7, 2017. Tramadol and hydrocodone/acetaminophen (Vicodin) are powerful pain relievers
Demystifying Opioid Conversion Calculations
Demystifying Opioid Conversion Calculations Stephanie Cheng, PharmD, MPH, BCGP Clinical Pharmacist Hospice Pharmacy Solutions November 28, 2018 Learning Objectives After this presentation, you should be
tablet/capsule Paracetamol 500mg
Formulary Item Restrictions and/or Advice Non-opioid analgesics + compound analgesic preparations Aspirin 75mg dispersible Aspirin 300mg dispersible Aspirin 300mg Aspirin 75mg EC Paracetamol 500mg / Paracetamol
Morphine Sulfate Hydromorphone Oxymorphone
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.33 Subject: Morphine Drug Class Page: 1 of 13 Last Review Date: September 15, 2016 Morphine Sulfate
Objectives. Controversy. Pain. Risk Stratification 1/7/2012
Objectives Strategies in Pain Management: Scheduled, Breakthrough, and Dose Adjustments Tamara M. Green, Pharm.D PGY-1 Resident Florida A & M University Classify and distinguish between different types
Levorphanol. Levorphanol Tartrate. Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.59 Subject: Levorphanol Page: 1 of 8 Last Review Date: March 17, 2017 Levorphanol Description Levorphanol
Morphine Sulfate Hydromorphone Oxymorphone
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.02.33 Subject: Morphine Drug Class Page: 1 of 8 Last Review Date: June 19, 2015 Morphine Sulfate Hydromorphone
Medical Policy An independent licensee of the Blue Cross Blue Shield Association
Opioids, Extended Release (ER) Page 1 of 12 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Opioids, Extended Release (ER) Prime Therapeutics will review Prior Authorization
Prior Authorization Guideline
Guideline GL-35952 Opioid Quantity Limit Overrides Formulary OptumRx Formulary Note: Approval Date 7/10/2017 Revision Date 7/10/2017 Technician Note: P&T Approval Date: 2/16/2010; P&T Revision Date: 7/12/2011
CHANGES TO YOUR DRUG LIST
CHANGES TO YOUR DRUG LIST More generics and lower-cost brands to help you stay healthy and save money At Cigna, it s our goal to offer you access to coverage for safe, effective and affordable medications.
Prescription Drug Abuse: Colorado and Nationwide
Prescription Drug Abuse: Colorado and Nationwide Eric Lavonas, MD Associate Director, Rocky Mountain Poison and Drug Center Associate Professor, University of Colorado School of Medicine 1 What s the Problem?
Urine Drug Testing Methods 3-5
Urine Drug Testing Methods 3-5 Type of Test Logistics Pearls Initial Screening Test: Immunoassay Confirmatory Test: Gas chromatography-mass spectrometry (GCMS) + or Liquid chromatography-mass spectrometry
2014 Quantity Limits (QL) Criteria
2014 Quantity Limits (QL) Criteria Certain drugs covered through your EmblemHealth Medicare HMO/PPO Medicare Plan are covered for only a limited quantity. We do this to ensure compliance with the US Food
Immediate Release Opioid Analgesics (Brand and Generic): Acute Pain Duration Limit with MME Limit and Post Limit Policy
BENEFIT APPLICATION DRUG POLICY Immediate Release Opioid Analgesics (Brand and Generic): Acute Pain Duration Limit with MME Limit and Post Limit Policy Benefit determinations are based on the applicable
Compensation Practice & Quality Department Replaced by PD#C10-1 January 27, 2017
Compensation Practice & Quality Department Replaced by PD#C10-1 January 27, 2017 PRACTICE DIRECTIVE #C10-1 TOPIC: Claims with Opioids, Sedative/Hypnotics or Other Prescribed Potentially Addictive Drugs
How To Green My Pharmacy. Prepared and presented by Luna El Bizri,Pharm-D, Community Pharmacist
How To Green My Pharmacy Prepared and presented by Luna El Bizri,Pharm-D, Community Pharmacist Learning Objectives At the end of this presentation, pharmacists will be able to : 1. Understand the negative
Long-Acting Opioid Analgesics
Market DC Long-Acting Opioid Analgesics Override(s) Prior Authorization Step Therapy Quantity Limit Approval Duration Initial request: 3 months Maintenance Therapy: Additional prior authorization required
No Pain, No Gain Pharmacy Patient Pain Counseling Competition
No Pain, No Gain Pharmacy Patient Pain Counseling Competition Offered by the Maine Pharmacy Association as part of the 2010 MPA Fall Conference Sponsored by an educational grant by NASPA and Purdue Pharma,